Bortezomib treatment increased arginylated calreticulin (R-CRT) in connection with SGs in the MO59K (apoptosis-resistant) cell line, while in the HOG (apoptosis-sensitive) cell line, SGs production was reduced, and R-CRT exhibits cytoplasmic distribution.R-CRT is required for tumor cells to respond to bortezomib therapy. The gene discussed is CALR; the disease is neoplasm.